Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment
Oncotelic Therapeutics reports progress on its proprietary AI platform and robotics integration, aiming to improve efficiency and compliance in pharmaceutical development and manufacturing.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced continued progress on its proprietary AI platform and robotics integration as it nears initial commercial deployment. The company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing.
The advancement marks a significant step for Oncotelic as it leverages artificial intelligence and robotics to streamline drug development processes. The PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration, now incorporates a vast repository of scientific literature. By automating workflows, the company aims to reduce manual effort and enhance accuracy in tasks related to drug manufacturing and quality control.
Oncotelic is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. In addition to its own drug pipeline, the company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
The company also engages in licensing and co-development through strategic partnerships and joint ventures. It currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The commercial deployment of the AI and robotics platform could have implications for the broader pharmaceutical industry, as it demonstrates the potential for automation to expedite drug development while maintaining regulatory compliance. By integrating vast datasets with robotic systems, Oncotelic may set a precedent for how biotech companies can leverage technology to reduce costs and time-to-market for new therapies.
For more information, the full press release is available at https://ibn.fm/2uitp. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.